In Vivo CAR-T Cell Production Shows Promising Clinical Results for Multiple Myeloma
The research team tested a technology that enables the production of CAR-T cells directly within the body. When applied to several patients with multiple myeloma, it demonstrated faster efficacy compared to conventional treatments. The elimination of the cell extraction and cultivation process reduces costs and significantly improves accessibility. Although further validation is required due to the preliminary nature of the data, this approach has the potential to revolutionize the field of immunotherapy.
Nature Medicine, Published online: 25 March 2026; doi:10.1038/s41591-026-04296-8. Early clinical data on in vivo CAR-T cell therapy for multiple myeloma reveals key mechanistic insights and could mark the beginning of a new era of fast, streamlined, and accessible immunotherapies.
The ability to produce CAR-T cells more quickly and affordably can greatly expand patient benefits